Sicare Bio

What Sicare Bio does

SiCare Bio is a pharmaceutical technology company operating as a business division of TruTag Technologies, Inc., headquartered in Kapolei, Hawaii, and launched in late 2024. The company commercializes the SiRx platform, a programmable drug delivery system built on high-precision nanoporous silicon dioxide (nPSi) particles engineered for the loading and sustained release of therapeutic payloads. Two product formats are offered: nPSi nanoparticles for targeted delivery of biologics and small molecules (including siRNA, mRNA, antibodies, and chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release applications. The platform is positioned to address specific shortcomings of existing drug delivery systems, notably lipid nanoparticle (LNP) limitations such as endosomal entrapment, and polymer-based systems' incompatibility with proteins and burst-release profiles.

The company operates as a B2B pharmaceutical partner, generating revenue through direct strategic co-development agreements with pharmaceutical companies. SiCare Bio engineers custom particles for each partner's unique therapeutic load and release profile, with revenue derived from development agreements and potential licensing of the SiRx platform. The disclosed pipeline spans six therapeutic areas: Age-Related Macular Degeneration (partnered with Spinnaker BioSciences, preclinical stage), mRNA Delivery, Oncology, Immunology, Contraception, and Neurology (all currently in discovery with undisclosed pharmaceutical partners).

Leadership comprises a six-person executive team with credentials spanning pharmaceutical quality (ex-Abbott, Kos Pharmaceuticals), porous silicon research (Michael Sailor with over 200 publications and 25+ patents), biotech commercialization, and law. The underlying nPSi manufacturing capability is built on more than a decade of R&D and scaled production by parent TruTag Technologies, which supplies kilograms-per-annum capacity. No external funding rounds or revenue figures are publicly disclosed.

Name

Sicare Bio

Legal name

TruTag Technologies, Inc.

Website

https://sicarebio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

SiCare Bio is a pharmaceutical technology company developing nanoporous silicon dioxide (nPSi) particle platforms for targeted and extended-release drug delivery. It serves pharmaceutical partners through custom co-development agreements across multiple therapeutic areas including ARMD, mRNA, oncology, and neurology.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Delivery Technology

NAICS

Research and Development in Nanotechnology (541713)

SIC

Miscellaneous Chemical Products (2890)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industry

Silica (Quartz, Fumed, Precipitated) (IMAEAFAD)

Keywords

• Nanoporous silica particles
• Drug delivery platform
• Targeted therapeutic delivery
• Extended-release drug delivery
• Pharmaceutical contract development

Headquarters

HQ city

Kapolei

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development Partnerships: SiCare Bio generates revenue through strategic partnerships with pharmaceutical companies, engineering custom nPSi particles for each partner's unique therapeutic load and release profile. Revenue is derived from development agreements and potentially licensing of the SiRx platform technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SiCare Bio engineers custom nanoporous silicon (nPSi) particles through its SiRx platform, a programmable drug delivery system that loads and sustains the release of therapeutic payloads for pharmaceutical development partners. The company offers two delivery modalities: nPSi nanoparticles for targeted delivery of biologics and small molecules (siRNA, mRNA, antibodies, chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release applications.

Product overview

SiCare Bio offers the SiRx platform, a core technology comprising high-precision, nanoporous silicon dioxide (nPSi) particles that serve as a programmable drug delivery system for pharmaceutical applications. The platform encompasses two primary product offerings: nPSi nanoparticles for targeted delivery of biologics and small molecules (including siRNA, mRNA, antibodies, and chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release drug delivery. The company operates pipeline programs across multiple therapeutic areas including ARMD (partnered with Spinnaker BioSciences), mRNA delivery, oncology, immunology, contraception, and neurology, all leveraging the core SiRx platform technology.

Differentiator

Problem solved

Functional benefit

Brands

• SiRx Platform: SiRx is the company's precision nanoporous silicon dioxide particle platform for delivering and sustaining release of therapeutic payloads, used as an innovative drug delivery system for development partners.

Products and services

• SiRx Platform Programmable drug delivery platform using high-precision nanoporous silicon (nPSi) particles for the loading and sustained release of therapeutic payloads, offered to pharmaceutical development partners as an innovative drug delivery system for extended-release and targeted delivery applications.
• nPSi Nanoparticles (Targeted Delivery) Engineered nanoporous silicon dioxide nanoparticles for targeted redosable delivery of biologic and small molecule payloads including siRNA, mRNA, antibodies, and chemotherapeutics, addressing shortcomings of lipid nanoparticle (LNP) drug delivery systems.
• nPSi Microparticles (pSiMPs - Extended-Release Delivery) Nanoporous silicon dioxide microparticles (pSiMPs) for extended-release drug delivery in which nanopores are filled with active pharmaceutical ingredient and released as particles break down in the body, offering advantages over traditional polymer-based systems including improved tolerability, custom release profiles, and aqueous-based loading compatible with proteins.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Spinnaker BioSciencescoreStrategic or Co-development PartnerSpinnaker BioSciences is partnered with SiCare Bio for ARMD (Age-Related Macular Degeneration) drug delivery application. The partnership is currently in preclinical stage, utilizing the SiRx platform for therapeutic delivery.
• TruTag TechnologiescoreOthersTruTag Technologies is the parent company of SiCare Bio. SiCare Bio was launched in late 2024 as a business division of TruTag Technologies, which is the global leader in manufacturing of high-precision, bio-compatible nanoporous silica. TruTag has dedicated over a decade of R&D to scalable manufacturing of these materials.
• Undisclosed Pharmaceutical PartnerscoreStrategic or Co-development PartnerMultiple undisclosed pharmaceutical partners are working with SiCare Bio on various therapeutic applications including mRNA Delivery, Oncology, Immunology, Contraception, and Neurology - all currently in Discovery stage.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Precision NanoSystems (Cytiva / Danaher): Precision Nanosystems (now part of Cytiva/Danaher) provides lipid nanoparticle development equipment and services for RNA and gene therapy developers — comparable as an incumbent RNA delivery tooling/services player operating in the same pharma partnership funnel.
• BioNTech: BioNTech is a leading mRNA therapeutics company with its own LNP formulation capabilities and multiple partnered programs — comparable as a broad incumbent shaping industry adoption of mRNA delivery technology.
• Alnylam Pharmaceuticals: Alnylam pioneered the GalNAc-conjugate siRNA delivery platform and remains the incumbent in hepatocyte-targeted RNA delivery — comparable as a dominant RNA delivery paradigm against which any new delivery platform (like SiRx) competes for therapeutic partnership demand.
• Catalent: Catalent provides drug delivery and formulation development services (including advanced biologics delivery) to pharma partners — comparable as a broad incumbent in development-stage delivery services with a partnership-driven GTM motion.
• Becton Dickinson (BD): BD's Pharmaceutical Systems segment supplies drug delivery devices (prefilled syringes, auto-injectors, needle-free systems) — comparable as an established pharma delivery incumbent whose customers overlap with SiCare Bio's target buyer base.
• West Pharmaceutical Services: West is a leading provider of drug delivery systems and containment for injectable therapeutics — comparable as a broader incumbent in pharmaceutical delivery and primary-packaging systems serving large pharma partners.

Direct peers

• Acuitas Therapeutics: Acuitas is the leading LNP delivery platform provider for nucleic acid therapeutics, partnering with multiple mRNA and gene-editing developers — the most direct comparable to SiCare Bio's SiRx delivery platform, which is positioned as an LNP alternative.
• Arcturus Therapeutics: Arcturus develops its own LNP delivery platform (LUNAR) for mRNA and siRNA therapeutics and licenses delivery to partners — a directly comparable integrated delivery platform + pipeline model with strong RNA delivery focus.
• Genevant Sciences: Genevant commercializes LNP and ligand-based nucleic acid delivery technology through partnerships with RNA therapeutic developers — directly comparable to SiCare Bio as an LNP-alternative delivery platform targeting siRNA/mRNA partners.

Emerging players

• Codiak BioSciences: Codiak developed engineered exosome-based delivery for RNA and protein therapeutics — comparable as an early-stage non-LNP, non-viral delivery platform seeking pharma partners for pipeline assets in oncology and immunology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/trutags
• YouTubeyoutube.com/channel/UChMab5V7CyHgjIhcUbpMOzw
• Facebookfacebook.com/trutags
• LinkedInlinkedin.com/company/sicarebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sicare Bio